Dr. Matthew Price, of Scripps Clinic, La Jolla, California, discusses with Dr. Ron Waksman 1-year clinical outcomes after transcatheter left atrial appendage occlusion (LAAO) for stroke prevention in patients with atrial fibrillation (AF). This report from the National Cardiovascular Data Registry (NCDR) LAAO Registry, which was presented as a late-breaking trial at ACC.21 Virtual, found that thromboembolic events were infrequent in patients implanted with the Watchman (Boston Scientific) LAAO device. Study investigators did recommend that clinicians should incorporate risks of bleeding and death unrelated to thromboembolism in the early post-discharge period when selecting a stroke-prevention strategy for AF patients who are unable to take long-term oral anticoagulation.